Treatment of anemia in pregnancy
Reading File
Finding Sources
Searching PubMed
"anemia" AND "pregnancy" AND "treatment"
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive data. Let me compile the full answer.
Treatment of Anemia in Pregnancy
Definition & Diagnosis
Anemia in pregnancy is defined by the CDC as a hemoglobin (Hb) < 11 g/dL in the first and third trimesters, or < 10.5 g/dL in the second trimester. Globally, it affects ~38% of pregnant women, with iron deficiency accounting for approximately half of cases. Screening is recommended in the first trimester and again at 24–28 weeks.
Key diagnostic distinction: Physiologic (dilutional) anemia — caused by a 47% rise in plasma volume vs. only 17% increase in RBC mass — does not change MCV or MCHC. A falling MCV or MCHC suggests true nutritional deficiency. Serum ferritin is the single best test to diagnose iron deficiency anemia (IDA) before anemia is clinically apparent; a ferritin < 20 µg/L indicates depletion.
1. Iron Deficiency Anemia (IDA) — 75% of Cases
Iron requirements during pregnancy are substantial — exceeding what is saved by 9 months of amenorrhea — and ~two-thirds of women begin pregnancy with marginal iron stores.
Prophylaxis / Supplementation
| Setting | Dose |
|---|---|
| All pregnant women (WHO) | 60 mg elemental iron + folic acid daily; 30 mg may suffice when given with micronutrients |
| Prevention (US guidelines) | 30 mg elemental iron as simple salts (ferrous sulfate, gluconate, or fumarate) |
Treatment of Established IDA
-
First-line: Oral iron — ferrous sulfate 325 mg (65 mg elemental iron) 1–3 times daily
- Reticulocytosis expected at 7–10 days; Hb rises up to 1 g/dL/week in severe anemia
- Absorption enhanced by co-administration of 500 mg ascorbic acid per dose
- GI side effects (nausea, constipation, cramps) are dose-dependent; reduce dose or switch to syrup (ferrous sulfate 300 mg/5 mL) if intolerable
- Continue for 6 months after resolution to replenish stores
- Consider vitamin B₆ supplementation if unresponsive, as B₆ declines in pregnancy and co-supplementation improves Hb response
-
Parenteral (IV) iron — no longer reserved only for malabsorption; now broadly used, especially in the second and third trimesters for:
- Moderate–severe IDA not tolerating oral iron
- Rapid correction needed near term
- Third trimester: IV iron is the treatment of choice for all IDA
- First trimester: IV iron is avoided
- Six preparations are FDA-approved: iron sucrose (most commonly used), ferric carboxymaltose, ferric gluconate, low-molecular-weight iron dextran, ferumoxytol, iron isomaltoside
- Test dose needed only with low-molecular-weight iron dextran (anaphylaxis otherwise rare)
- Dose formula for iron sucrose: weight (kg) × (target Hb – actual Hb) × 0.24 + 500 mg; target Hb = 11–12 g/dL
-
Blood transfusion — reserved for severe anemia (Hb < 6 g/dL) with signs of fetal compromise (non-reassuring fetal heart rate, reduced amniotic fluid, fetal cerebral vasodilatation)
⚠️ Failure to respond to oral iron should prompt reassessment: incorrect diagnosis, malabsorption (especially with enteric-coated tablets or concurrent antacids), non-compliance, ongoing blood loss, or coexisting thalassemia.
2. Megaloblastic Anemia (Folate / B₁₂ Deficiency)
Folate deficiency is the second most common nutritional anemia in pregnancy.
- Treatment: Folic acid 1–5 mg/day orally
- Prevention: All women of reproductive age should take 0.4–0.8 mg/day preconceptionally and throughout pregnancy; those with prior neural tube defect pregnancy require 4 mg/day
- Folate deficiency during pregnancy is now less common due to widespread supplementation and food fortification
Vitamin B₁₂ deficiency is rare in pregnancy but seen in strict vegans.
- Treatment: Vitamin B₁₂ supplementation or IM cyanocobalamin
3. Hemoglobinopathies
Thalassemia
- α-Thalassemia minor / β-Thalassemia trait: No treatment required; counsel regarding genetic risk to fetus; iron supplementation only if iron deficiency is confirmed (iron is not indicated for thalassemia alone)
- β-Thalassemia major: Chronic transfusion support; splenectomy may reduce transfusion requirements; periconceptional counseling essential
- Hb H disease: Transfusion as needed for severe hemolysis
Sickle Cell Anemia (HbSS)
Higher-risk pregnancy: increased rates of preeclampsia, preterm birth, VTE, ACS, sepsis, and maternal mortality.
| Management | Details |
|---|---|
| Folic acid | 4 mg/day (increased requirements from hemolysis) |
| Pain crises | Treat same as non-pregnant: IV fluids, analgesia (opioids acceptable, NSAIDs avoid in 3rd trimester); supplemental O₂ |
| Hydroxyurea | Contraindicated — teratogenic |
| Transfusion | For acute chest syndrome, severe anemia, stroke, preoperative preparation; exchange transfusion for ACS |
| Thromboprophylaxis | Low-molecular-weight heparin (LMWH) recommended on antepartum admissions |
| Penicillin prophylaxis | Continue if already on it (asplenic patients) |
4. Autoimmune Hemolytic Anemia (AIHA)
- Warm-type: Corticosteroids first-line (~80% response rate); splenectomy as second-line; rituximab (anti-CD20) used successfully in refractory cases during pregnancy without known adverse fetal outcomes
- Cold-type: Mild — avoid cold exposure; severe — trial of immunosuppression or plasmapheresis; corticosteroids and splenectomy generally ineffective
5. Anemia of Chronic Disease / Renal Failure
- Does not respond to hematinic agents
- Erythropoietin is useful in chronic renal failure and can reduce need for repeated transfusions (a 2025 systematic review [PMID 39087437] found recombinant erythropoietin beneficial for IDA in pregnancy in selected cases)
Key Monitoring Parameters
| Parameter | Target |
|---|---|
| Hb | ≥ 11 g/dL (T1, T3); ≥ 10.5 g/dL (T2) |
| Serum ferritin | > 20 µg/L |
| Reticulocyte response to iron | Day 7–10 post-initiation |
| Hb rise with iron therapy | ~1 g/dL/week |
Recent Evidence (2024–2025)
- A 2024 Cochrane meta-analysis (PMID 39145520) confirmed daily oral iron supplementation during pregnancy reduces the risk of IDA and low birthweight; optimal dose and formulation remain under study
- A 2024 USPSTF evidence review (PMID 39163033) in JAMA updated the evidence base for screening and supplementation for iron deficiency in pregnancy
- A 2025 systematic review (PMID 39087437) in Int J Gynaecol Obstet found recombinant erythropoietin is a viable adjunct for IDA in pregnancy in select patients, though evidence remains limited
Sources: Creasy & Resnik's Maternal-Fetal Medicine, 8th ed., Ch. 55; Textbook of Family Medicine, 9th ed.; Harrison's Principles of Internal Medicine, 22nd ed. (2025); Rosen's Emergency Medicine, 9th ed.
This is a shared conversation. Sign in to Orris to start your own chat.